SCLC

Question 1

Systemic therapy as primary or adjuvant therapy:

• Limited stage (maximum of 4–6 cycles):

Answer 1

Cisplatin 60 mg/m2 day 1 and etoposide 120 mg/m2 days 1, 2, 3

Cisplatin 80 mg/m2 day 1 and etoposide 100 mg/m2 days 1, 2, 3

Carboplatin AUC 5–6 day 1 and etoposide 100 mg/m2 days 1, 2, 3

During systemic therapy + RT, cisplatin/etoposide is recommended (category 1)

The use of myeloid growth factors is not recommended during concurrent systemic therapy plus radiotherapy (category 1 for not using GM-CSF)

Question 2

Systemic therapy as primary or adjuvant therapy:

• Extensive stage (maximum of 4–6 cycles):

Answer 2

Carboplatin AUC 5–6 day 1 and etoposide 100 mg/m2 days 1, 2, 3

Cisplatin 75 mg/m2 day 1 and etoposide 100 mg/m2 days 1, 2, 3

Cisplatin 80 mg/m2 day 1 and etoposide 80 mg/m2 days 1, 2, 3

Cisplatin 25 mg/m2 days 1, 2, 3 and etoposide 100 mg/m2 days 1, 2, 3

Carboplatin AUC 5 day 1 and irinotecan 50 mg/m2 days 1, 8, 15

Cisplatin 60 mg/m2 day 1 and irinotecan 60 mg/m2 days 1, 8, 15

Cisplatin 30 mg/m2 and irinotecan 65 mg/m2 days 1, 8

Question 3

Systemic therapy as primary or adjuvant therapy:

• Relapse ≤6 mo, PS 0-2:

Answer 3

topotecan PO or IV
irinotecan
paclitaxel
docetaxel
temozolomide
nivolumab ± ipilimumab
vinorelbine
oral etoposide
gemcitabine
cyclophosphamide/doxorubicin/vincristine (CAV)
bendamustine (category 2B)